Mereo Biopharma Group Plc ADR (MREO)

Jan 12, 2025, 11:05 AM EST - 5 days ago

Mereo BioPharma Provides Update on Lead Clinical Programs

Jan 7, 2025, 7:30 AM EST - 10 days ago

Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 26, 2024, 1:36 PM EST - 7 weeks ago

Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points

Nov 14, 2024, 7:30 AM EST - 2 months ago

Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Nov 12, 2024, 7:30 AM EST - 2 months ago

Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Sep 12, 2024, 5:35 PM EDT - 4 months ago

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference

Aug 13, 2024, 8:00 AM EDT - 5 months ago

Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 14, 2024, 7:50 AM EDT - 7 months ago

Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market

May 30, 2024, 7:30 AM EDT - 8 months ago

Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

May 15, 2024, 4:01 PM EDT - 8 months ago

Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 3, 2024, 7:30 AM EDT - 10 months ago

Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

Mar 27, 2024, 4:01 PM EDT - 10 months ago

Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update

Mar 14, 2024, 5:34 PM EDT - 11 months ago

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

KRRO KRYS TAK WVE

Mar 5, 2024, 7:30 AM EST - 11 months ago

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference

Jan 8, 2024, 7:00 AM EST - 1 year ago

Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments

Oct 23, 2023, 4:01 PM EDT - 1 year ago

Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update

Sep 21, 2023, 7:00 AM EDT - 1 year ago

Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference

Sep 7, 2023, 7:30 AM EDT - 1 year ago

Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update

May 31, 2023, 7:00 AM EDT - 1 year ago

Mereo BioPharma to Present at the Jefferies Healthcare Conference

May 23, 2023, 1:43 PM EDT - 1 year ago

Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

May 8, 2023, 12:46 PM EDT - 1 year ago

Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 5, 2023, 4:06 PM EDT - 1 year ago

Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market

Mar 28, 2023, 4:30 PM EDT - 1 year ago

Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights

Mar 21, 2023, 6:30 AM EDT - 1 year ago

Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease

Feb 8, 2023, 7:00 AM EST - 2 years ago

Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference

Nov 2, 2022, 4:01 PM EDT - 2 years ago

Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency

Oct 28, 2022, 7:00 AM EDT - 2 years ago

Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

Oct 24, 2022, 4:30 PM EDT - 2 years ago

Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022

Oct 21, 2022, 7:00 AM EDT - 2 years ago

Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting

Oct 18, 2022, 11:58 AM EDT - 2 years ago

Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan

Oct 18, 2022, 7:00 AM EDT - 2 years ago

Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value

Oct 17, 2022, 7:00 AM EDT - 2 years ago

Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease

Oct 3, 2022, 5:00 PM EDT - 2 years ago

Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders

Oct 3, 2022, 9:00 AM EDT - 2 years ago

Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five

Sep 26, 2022, 7:00 AM EDT - 2 years ago

Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board

Sep 22, 2022, 1:45 PM EDT - 2 years ago

Mereo BioPharma: An Activist Pressure With A Potentially Significant Upside

Sep 14, 2022, 9:00 AM EDT - 2 years ago

Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders

Sep 12, 2022, 8:00 AM EDT - 2 years ago

Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors

Aug 31, 2022, 7:00 AM EDT - 2 years ago

Mereo BioPharma Sends Letter to Rubric Capital Management

Jun 17, 2022, 10:39 AM EDT - 2 years ago

Why Mereo BioPharma Shares Are Jumping Today

Jun 17, 2022, 3:44 AM EDT - 2 years ago

AstraZeneca weighing bid for Mereo BioPharma: report

AZN

May 26, 2022, 5:05 PM EDT - 2 years ago

Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting

May 9, 2022, 7:47 AM EDT - 2 years ago

Mereo BioPharma Shares Jump After Encouraging Alvelestat Data In Lung Disease

May 6, 2022, 5:12 PM EDT - 2 years ago

Mereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat

May 6, 2022, 5:12 PM EDT - 2 years ago

Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat

Apr 6, 2022, 8:00 AM EDT - 3 years ago

Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference

Mar 31, 2022, 4:01 PM EDT - 3 years ago

Mereo BioPharma Reports Full Year 2021 Financial Results and Recent Highlights

Feb 10, 2022, 8:00 AM EST - 3 years ago

Mereo BioPharma to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference

Dec 22, 2021, 12:44 PM EST - 3 years ago

Mereo BioPharma's Alvelestat Shows Improvement In COVID-19 Severity

Dec 22, 2021, 7:00 AM EST - 3 years ago

UAB and Mereo Announce Positive Top-line Results from “COSTA” a Phase 1b/2 Trial of Alvelestat (MPH966) in Hospitalized Patients with COVID-19 Respiratory Disease